Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Egetis Therapeutics AB paidkr0.00 Mil more to buy back shares than it received from issuing new shares.
It spentkr7.50 Mil paying down its debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It receivedkr0.00 Mil on other financial activities.
In all, Egetis Therapeutics ABspentkr7.50 Mil on financial activities for the
three
months ended in Mar. 2026.
Egetis Therapeutics AB (LTS:0ABW) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Egetis Therapeutics AB's issuance of stock for the
three
months ended in Mar. 2026 was kr0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Egetis Therapeutics AB's repurchase of stock for the
three
months ended in Mar. 2026 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Egetis Therapeutics AB's net issuance of debt for the
three
months ended in Mar. 2026 was kr-7.50 Mil.
Egetis Therapeutics AB spentkr7.50 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Egetis Therapeutics AB's net issuance of preferred for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Egetis Therapeutics AB paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Egetis Therapeutics AB's cash flow for dividends for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Egetis Therapeutics AB receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Egetis Therapeutics AB's other financing for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Egetis Therapeutics AB receivedkr0.00 Mil on other financial activities.
Egetis Therapeutics AB Cash Flow from Financing Related Terms
Egetis Therapeutics AB Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Egetis Therapeutics AB's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egetis Therapeutics AB Cash Flow from Financing Chart
Egetis Therapeutics AB Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Egetis Therapeutics AB's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr139.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr139.40 Mil mean?
Egetis Therapeutics AB (LTS:0ABW) has a Cash Flow from Financing of kr139.40 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Cash Flow from Financing too high?
Egetis Therapeutics AB's current Cash Flow from Financing is kr139.40 Mil. Overall, Egetis Therapeutics AB has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Cash Flow from Financing compare to VRTX and REGN?
Egetis Therapeutics AB's Cash Flow from Financing of kr139.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Cash Flow from Financing is kr139.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.67, compared to a current price of kr6.82 — trading 20.3% above its estimated fair value. The current Cash Flow from Financing is kr139.40 Mil. Egetis Therapeutics AB's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Cash Flow from Financing is kr139.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr6.82 is trading 20.3% above its estimated GF Value™ of kr5.67.
GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.
Key valuation signals for LTS:0ABW:
Cash Flow from Financing: kr139.40 Mil
GF Value™: kr5.67 vs. price of kr6.82 (20.3% above fair value)
No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
61GF Score
Get the complete analysis for LTS:0ABW
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ABW has been successfully added to your 
